PolyNovo Limited (CALZF)
OTCMKTS · Delayed Price · Currency is USD
0.8180
0.00 (0.00%)
Sep 3, 2025, 8:00 PM EDT
PolyNovo Revenue
In the fiscal year ending June 30, 2025, PolyNovo had annual revenue of 128.70M AUD with 24.67% growth. PolyNovo had revenue of 69.16M in the half year ending June 30, 2025, with 90.62% growth.
Revenue
128.70M AUD
Revenue Growth
+24.67%
P/S Ratio
8.19
Revenue / Employee
427.57K AUD
Employees
301
Market Cap
691.34M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2025 | 128.70M | 25.47M | 24.67% |
Jun 30, 2024 | 103.23M | 37.56M | 57.20% |
Jun 30, 2023 | 65.67M | 23.78M | 56.76% |
Jun 30, 2022 | 41.89M | 12.55M | 42.78% |
Jun 30, 2021 | 29.34M | 7.15M | 32.19% |
Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Elite Pharmaceuticals | 105.45M |
Tian'an Technology Group | 2.12M |
Glass House Brands | 221.55M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Longduoduo Company | 4.99M |
PolyNovo News
- 6 months ago - PolyNovo chief executive steps down after dispute with chairman - The Australian Financial Review
- 6 months ago - David Williams says he makes no apologies for ‘aggressive’ style - The Australian Financial Review
- 1 year ago - Polynovo Ltd (CALZF) (Q4 2024) Earnings Call Transcript Highlights: Record Revenue and ... - GuruFocus